Clinical Trials Directory

Trials / Conditions / Refractory AML

Refractory AML

16 registered clinical trials studyying Refractory AML — 7 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingRadioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
NCT07157514
Actinium PharmaceuticalsPhase 2 / Phase 3
RecruitingChiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML
NCT06737523
The First Affiliated Hospital of Xiamen UniversityPhase 1
Active Not RecruitingCART123 + Ruxolitinib in Relapsed/Refractory AML
NCT06768476
University of PennsylvaniaPhase 1
WithdrawnTislelizumab with Azacitidine in the Treatment of R/R AML
NCT06586099
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1 / Phase 2
WithdrawnVenetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid
NCT06007911
Medical College of WisconsinPhase 1
RecruitingCLL-1 CAR-NK Cells for Relapsed/Refractory AML
NCT06307054
Shanghai General Hospital, Shanghai Jiao Tong University School of MedicinePhase 1
RecruitingSafety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
NCT06316960
Children's Hospital of Soochow UniversityPhase 2
RecruitingStudy Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilter
NCT06022003
French Innovative Leukemia OrganisationPhase 2
RecruitingA Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, V
NCT05735184
Kura Oncology, Inc.Phase 1
UnknownAn Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia
NCT05226468
New Epsilon Innovation LimitedPhase 1
CompletedA Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloi
NCT05193448
French Innovative Leukemia Organisation—
UnknownTrial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)
NCT04330820
Technische Universität DresdenPhase 1 / Phase 2
TerminatedNatural Killer Cell (CYNK-001) Infusions in Adults with AML
NCT04310592
Celularity IncorporatedPhase 1
RecruitingClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43
NCT03850574
Aptose Biosciences Inc.Phase 1 / Phase 2
TerminatedDose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia
NCT03516760
AvenCell Europe GmbHPhase 1
CompletedPhase 1 Study of Quizartinib
NCT02675478
Daiichi Sankyo Co., Ltd.Phase 1